BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27604413)

  • 1. Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1.
    Zhou X; Hendrickx ML; Hassanzadeh-Ghassabeh G; Muyldermans S; Declerck PJ
    Thromb Haemost; 2016 Nov; 116(6):1032-1040. PubMed ID: 27604413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
    Sillen M; Weeks SD; Zhou X; Komissarov AA; Florova G; Idell S; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2020 Mar; 18(3):681-692. PubMed ID: 31858714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity.
    Sillen M; Weeks SD; Strelkov SV; Declerck PJ
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S; Declerck PJ
    Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody.
    Hendrickx ML; Zatloukalova M; Hassanzadeh-Ghassabeh G; Muyldermans S; Gils A; Declerck PJ
    Thromb Haemost; 2014 May; 111(5):824-32. PubMed ID: 24402608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serine proteinases.
    Debrock S; Declerck PJ
    FEBS Lett; 1995 Dec; 376(3):243-6. PubMed ID: 7498551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
    Wind T; Jensen MA; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
    Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
    Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope mapping of monoclonal antibodies directed to PAI-1 using PAI-1/PAI-2 chimera and PAI-1-derived synthetic peptides.
    Muehlenweg B; Guthaus E; de Prada NA; Schmitt M; Schmiedeberg N; Kotzsch M; Creutzburg S; Kramer MD; Kessler H; Wilhelm OG; Magdolen V
    Thromb Res; 2000 Apr; 98(1):73-81. PubMed ID: 10706935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis.
    Stringer HA; van Swieten P; Horrevoets AJ; Smilde A; Pannekoek H
    Thromb Haemost; 1994 Dec; 72(6):900-5. PubMed ID: 7740461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
    Debrock S; Declerck PJ
    Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor-1.
    Björquist P; Ehnebom J; Deinum J
    Biochim Biophys Acta; 1999 Apr; 1431(1):24-9. PubMed ID: 10209275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
    Robbie LA; Booth NA; Croll AM; Bennett B
    Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.